Pharmaceutical Manufacturer Assertio Therapeutics Inc. Agrees to Pay $3.6M to Resolve Allegations that It Violated the False Claims Act in Connection with Marketing its Fentanyl Product - FedKite: AI-Driven Solutions and Resources for Federal Inmates & Families

This topic is empty.

Viewing 0 reply threads

Author

Posts
- May 11, 2025 at 3:15 am #9820
  
  Kris Marker
  Keymaster
  
  The Justice Department announced today that Assertio Therapeutics Inc., formerly known as Depomed Inc., (Assertio), a pharmaceutical company headquartered in Lake Forest, Illinois, has agreed to pay $3.6 million to resolve claims that Assertio violated the False Claims Act (FCA) by causing the submission of false claims for the transmucosal immediate-release fentanyl (TIRF) drug Lazanda for individuals who did not have breakthrough cancer pain.
Author

Posts

Viewing 0 reply threads

You must be logged in to reply to this topic.